Driven in part by advances in imaging technology, clinical staging in lymphoma has evolved significantly since the 1970s. At the NCCN 2020 Virtual Congress: Hematologic Malignancies, Leo I. Gordon, MD, Abby & John Friend Professor of Cancer Research, Professor in Medicine, and Co-Director of the Hematologic Malignancies Program, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discussed the history of staging using Hodgkin lymphoma as a model, uniform staging criteria for clinical trials, the evolution of response criteria, and graphic representations of clinical trial data.
Carbone PP, Kaplan HS, Musshoff K, Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971;31:1860–1861.
Lister TA, Crowther D, Sutcliffe SB, Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
Cheson BD, Fisher RI, Barrington SF, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059–3068.
Cheson BD, Ansell S, Schwartz L, Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016;128:2489–2496.
Younes A, Hilden P, Coiffier B, International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017;28:1436–1447.